Onalabs Closes a Capital Increase of €1.8 Million

Onalabs, a start-up aimed at developing medical devices capable of reading, measuring, and monitoring physical and biochemical parameters of the skin through sweat, has announced the closing of a capital increase of €1.8 million. Through this move, the Barça Innovation Hub has joined the shareholders as a new strategic partner. In this way, Onalabs has assured that it will manage to double its valuation compared to last year.  

The company has announced that Barça Innovation Hub will contribute its main non-monetary assets and will contribute to the national and international drive of the company. In fact, the entity, whose mission is to encourage and promote innovation in the sports sector, has assured that it is betting on Onalabs to be able to jointly evolve the Onasport device, which will activate the pre-sale campaign during this third quarter.

The firm describes Onasport as “a portable monitoring solution in chest strap format that measures, in real-time and continuously, remotely and non-invasively, lactate level, heart rate, electrolyte loss and dehydration through of sweat.”  

Read more about Onalabs and find the latest financial news of the day with our companion app Born2Invest.

Onasport, Onalabs’ portable monitoring solution, will activate the pre-sale campaign during this third quarter

Elisabet del Valle, co-founder and executive director of Onalabs, has assured that “the entry as a partner of Barça Innovation Hub will allow us to create a disruptive alliance to reinforce knowledge and leadership in this area, and represents the beginning of great changes and new paradigms in “training and monitoring of sports health,” according to the director’s words.

Barça Innovation Hub had already participated in two other start-ups before Onalabs: Visualfy, a company that promotes accessibility for deaf and hearing-impaired people; and Oliver, who has created a solution that makes data management accessible in grassroots sports clubs to improve the performance of their athletes.

Onlabas relied on Lanzadera to go on the market in September of last year. The firm, created by Elisabet del Valle and Xavi Muñoz, is focused on the development of three digital devices based on sensory bioengineering: L10, aimed at sports measurements; HAD10, focused on chronic diseases; and a third aimed at monitoring diabetes.

The wearables developed by the company, which are worn on the skin, act as micro-laboratories and aim to translate the language of biochemistry into useful data for both professionals and users. L10 and HAD10 have been validated in centers such as the Germans Trias i Pujol Hospital in Badalona (Barcelona), the High-Performance Sports Center (CAR) in Sant Cugat, and the National Institute of Physical Education of Catalonia (Inefc).

__

(Featured image by namair via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.